Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preemptive Therapy With Venetoclax for High Risk Chronic Lymphoid Leukemia Stage A Patients, a Phase II Trial of the FILO

NCT03766763 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT03766763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03766763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preemptive Therapy With Venetoclax for High Risk Chronic Lymphoid Leukemia Stage A Patients, a Phase II Trial of the FILO
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 22, 2019
Completion date
April 24, 2030
Enrollment
82 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphoid leukemia